Thesis
French
ID: <
10670/1.3qeva3>
Abstract
Because of its complex pathology, Traumatic Brain Injury (TBI) leads to numerous cerebral lesions for which there is no neuroprotective treatment. It is clearly known nowadays that neuro-inflammation is highly involved in post-traumatic consequences. This devastating process is manifested among others by the induction of cyclo-oxygenase type 2 (COX-2). Although many data are in agreement with a deleterious role of COX-2 in neuro-inflammation, the implication of this isoform in the TBI-induced lesions is still controversial. In a mouse model of TBI induced by mechanical percussion, we have shown an early and a transitory increase in the cerebral content of COX-2 at 6 and 12 hours after trauma. This protein induction was the source of an increased production of prostacyclin. However, the preferential inhibition of COX-2 had no effect against cerebral œdema and neurological deficit, two indicators of high clinical relevance. These data show that COX-2 cannot be considered by itself as an interesting target for the treatment of post-traumatic consequences despite its induction and activity after trauma. Besides, we have shown a beneficial effect that was induced by indomethacin at the functional level. This effect highly suggests a deleterious role of COXs in the post-traumatic neurological deficit. This neuroprotection could solely involve COX-1 or both COX isoforms. In accordance with several proofs that were recently supplied by literature, our data constitute an additional argument suggesting a deleterious role of COX-1 in neuro-inflammation. Unfortunately, this hypothesis cannot be confirmed in our model of TBI because the selective inhibitors of COX-1 available this day cannot be exploited in our experimental conditions. This experimental work is a new indication to evaluate the potential interest of COXs inhibition during the early phase of clinical management of patients with TBI. The good tolerance of the short-term intake of COX inhibitors, their availability on the market, their affordable price, their simple way of administration, their well-known pharmacokinetic and pharmacodynamic characteristics increase the need to widen the spectrum of their therapeutic indications and to design new clinical trials during the upcoming years.